HomepageMedicineFDA Approves Bristol Myers Squibb’s Cobenfy for Schizophrenia Medicine FDA Approves Bristol Myers Squibb’s Cobenfy for Schizophrenia admin Posted on September 28, 2024 Landmark FDA approval of Cobenfy represents the first new class of drugs indicated to treat schizophrenia in decades. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous PostWhy Do My Cats Farts Smell Like Eggs? Our Vet Explains Next PostChristian Louboutin Makes a Splash at Paris Fashion Week You Might Also Like Medicine Avoiding the Digital Age is Hurting Research Efforts admin May 11, 2024 Medicine Potential Treatment Against All COVID Variants admin September 7, 2024 Medicine Gilead Appoints Dietmar Berger as Chief Medical Officer admin December 13, 2024 Medicine Bristol Myers Squibb Reveals Promising Data for KarXT, a Potential Treatment for Schizophrenia admin April 9, 2024
Medicine Bristol Myers Squibb Reveals Promising Data for KarXT, a Potential Treatment for Schizophrenia admin April 9, 2024